A Study of NB003 in Patients with Advanced Malignancies
- Registration Number
- NCT04936178
- Lead Sponsor
- Ningbo Newbay Technology Development Co., Ltd
- Brief Summary
This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies
- Detailed Description
This is a phase 1, open-label, multicenter study of NB003 which comprised of a dose escalation phase to determine the MTD or maximum administered dose (MAD), and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of NB003.
The dose escalation phase will enroll patients with advanced gastrointestinal stromal tumor (GIST) who have progressed on or had an intolerability to imatinib and other standard of cares (SoCs) or refused other SoCs, and patients with advanced malignancies other than GIST that harbors KIT or PDGFRα gene alterations who have relapsed or have refractory disease without an available effective therapy. The number of patients to be enrolled during the dose escalation part will vary depending on the underlining dose-toxicity curve and the number of dose levels tested prior to reaching MTD or MAD. After the MTD or MAD has been determined, based on emerging safety/PK data, one or more putative RP2D(s) will be explored in dose escalation phase with approximately 15 patients for each provisional RP2D(s) to establish the RP2D for dose expansion phase. This step will be regarded as RP2D confirmation part of dose escalation phase.
In the dose expansion phase, additional patients will be enrolled to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα. Dose expansion phase is planned to investigate NB003 at the RP2D determined from dose escalation phase.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 258
-
Males or females of any race ≥18 years age.
-
Histologically-confirmed diagnosis of unresectable, relapsed or metastatic GIST or other advanced malignancies.
-
For dose escalation phase:
- GIST patients must have progressed on or had an intolerability to imatinib and other SoCs or refused other SoCs.
- Patients with an advanced solid tumor other than GIST must have relapsed or had refractory disease without an available effective therapy and harbor KIT or PDGFRα gene alterations (central laboratory confirmation is not required for screening).
-
For dose expansion phase:
Cohort 1: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to at least imatinib, sunitinib, regorafenib and ripretinib (≥ fifth line therapy setting); Cohort 2a: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib and sunitinib, and who have not received additional systemic therapy for advanced GIST (third line therapy setting); Cohort 2b: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib, sunitinib and regorafenib, and who have not received additional systemic therapy for advanced GIST (forth line therapy setting); Cohort 3: GIST patients with KIT or PDGFRα gene mutations, must have progressed on or been intolerant to imatinib and have not received additional systemic therapy for advanced GIST (second line therapy setting); Cohort 4: GIST patients with PDGFRα exon 18 mutation and must have progressed on or been intolerant to avapritinib; in the countries/regions where avapritinib is not SoC, avapritinib-naïve patients can be enrolled; Cohort 5: Unresectable or metastatic melanoma patients with demonstrated evidence for KIT gene mutation and/or amplification, must have progressed on or been intolerant to SoCs; Cohort 6: Patients with other advanced malignancies other than GIST or melanoma which must be relapsed or refractory without an available effective therapy and harbor KIT or PDGFRα gene alterations.
-
-
For dose expansion phase: at least one measurable lesion per RECIST v1.1/mRECIST.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Life expectancy ≥ 12 weeks.
-
Adequate organ and marrow function.
-
Tumor sample collection is required.
- Prior anti-cancer therapy within 2 weeks or at least 5 half-lives, whichever is longer, up to a maximum wash-out period of 21 days prior to the initiation of study drug administration.
- Major surgery within 4 weeks of the first dose.
- Radiotherapy with a limited field of radiation for palliation within 1 week prior to the first dose, with the exception as defined.
- Patients currently receiving medications or herbal supplements known to be strong inhibitors or inducers of CYP3A4.
- Patients currently receiving acid-reducing agents and are unable to stop use at least 2 weeks prior to the first dose.
- Any known active central nervous system metastases and/or carcinomatous meningitis. Active infection including hepatitis B, hepatitis C, and HIV.
- Any other clinically significant comorbidities, such as uncontrolled pulmonary disease, active infection, uncontrolled pericardial effusion, uncontrolled pleural effusion, or any other conditions, which in the judgment of Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
- Any evidence of severe or uncontrolled systemic diseases which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Dose Escalation Phase and Dose Expansion Phase NB003 tablets Dose escalation cohort: NB003 tablets will be administered orally twice daily for repeated 28-day cycles until discontinuation criteria are met. RP2D: one or more putative RP2D(s) will be explored in dose escalation phase with approximately 15 patients for each provisional RP2D(s) Dose expansion phase: In the dose expansion phase, additional patients will be enrolled at RP2D to further explore the safety, tolerability, PK, efficacy and biological activity of NB003 in specific disease cohorts, including GIST and other malignancies harboring genomic alterations of KIT or PDGFRα.
- Primary Outcome Measures
Name Time Method Objective Response Rate (ORR) Approximately 26 months since the Expansion first subject enrolled Dose Expansion Phase: Objective Response Rate (ORR) which is defined as the percentage of patients whose efficacy is confirmed as complete response(CR) or partial responses(PR)
Incidence of dose-limiting toxicities Approximately 24 months since the escalation first subject enrolled Dose Escalation Phase：Dose-limiting toxicities will be reviewed as a subset of adverse events that occur within the first 28 days of dosing and meet protocol-specified criteria.
Incidence of adverse events Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled Dose Escalation Phase and Dose Expansion Phase: An AE is any untoward medical occurrence in a participant who received study drug without regard to causal relationship.
Duration of Response(DOR) Approximately 26 months since the Expansion first subject enrolled. Dose Expansion Phase: DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR.
- Secondary Outcome Measures
Name Time Method Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t) Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled Dose Escalation Phase and Dose Expansion Phase: AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.
Objective Response Rate (ORR) Approximately 24 months since the escalation first subject enrolled Dose Escalation Phase: Objective Response Rate (ORR) which is defined as the percentage of patients whose efficacy is confirmed as complete response(CR) or partial responses(PR)
Time to Cmax (Tmax) Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled Dose Escalation Phase and Dose Expansion Phase: Time to Cmax (Tmax)
Maximum observed plasma concentration (Cmax) Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled Dose Escalation Phase and Dose Expansion Phase: Maximum observed plasma concentration (Cmax)
Terminal elimination half life Approximately 24 months since the escalation first subject enrolled; Approximately 26 months since the Expansion first subject enrolled Dose Escalation Phase and Dose Expansion Phase: Terminal elimination half life
Duration of Response(DOR) Approximately 24 months since the escalation first subject enrolled Dose Escalation Phase: DOR is defined as the time from the date of first documented response until date of documented progression, for subjects who achieve CR or PR.
Trial Locations
- Locations (32)
Standford University
🇺🇸Stanford, California, United States
Mayo Clinic
🇺🇸Jacksonville, Florida, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
🇺🇸Long Island, New York, United States
Oregon Health & Science University (OHSU)
🇺🇸Portland, Oregon, United States
U T MD Anderson Cancer Center Investigational Pharmacy Services
🇺🇸Houston, Texas, United States
The Second Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China
Peking University People's Hospital
🇨🇳Beijing, Beijing, China
The First Affiliated Hospital of Chongqing Medical University
🇨🇳Chongqing, Chongqing, China
Fujian Cancer Hospital
🇨🇳Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, guandong, China
Xiangya Hospital, Central South University
🇨🇳Changsha, Huanan, China
West China Hospital, Sichuan University
🇨🇳Chengdu, Sichuan, China
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
The First Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou, guandong, China
The Affiliated Hospital of Qingdao University
🇨🇳Qingdao, Shandong, China
Centre Léon Bérard
🇫🇷Lyon cedex 08, Rhone, France
Harbin Medical University Cancer Hospital
🇨🇳Ha'erbin, Heilongjiang, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The Affiliated Hospital of Nanjing University Medical School
🇨🇳Nanjing, Jiangsu, China
Liaoning Cancer Hospital & Institute
🇨🇳Shenyang, Liaoning, China
The Second Affiliated Hospital of Xi'An Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
🇨🇳Tianjin, Tianjin, China
The First Affiliated Hospital of Zhejiang University school of medicine
🇨🇳Hangzhou, Zhejiang, China
Institut Gustave Roussy
🇫🇷Villejuif cedex, Val de Marne, France
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
🇨🇳Shanghai, Shanghai, China
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Royal Marsden Hospital-London
🇬🇧London, United Kingdom